Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Apr 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lineage Cell Therapeutics, Inc. (LCTX)
CIK: 0000876343
Period of Report: 2021-03-15

Reporting Person: Hernandez Alexandra (Sr Director Finance/Controller)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-30	Common Shares, no par value	M	6000	$0.6919	Acquired	6000	Direct
2021-03-30	Common Shares, no par value	S	6000	$2.23	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-15	Employee Stock Option (Right to Buy)	$2.43	A	42700	Acquired	2031-03-15	Common Shares (42700)	Direct
2021-03-30	Employee Stock Option (Right to Buy)	$0.6919	M	6000	Disposed	2030-03-17	Common Shares (6000)	Direct

Footnotes

F1: One quarter of the options vest on March 15, 2022 and the balance vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.

F2: One quarter of the options vested on March 17, 2021 and the balance vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.